Page 38 - Clinical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Patients receiving cancer care in Calgary are another step closer to receiving that care in a world-class medical centre. 

In these patients, we want to avoid as much as possible an over—treatment that can be considered in itself as a new disease, so that's why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who's used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard i information, the standard cli...

We know that for this type of cancer, the prognosis is good, with more than 90% of patients be able to get rid of the disease. in these patients, we want to avoid as much as possible an over—treatment that can be considered in itself as a new disease, so that's why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who's used to having difficult conversations with patients...

I'm very grateful. but how does he possibly i'm very grateful. but how does he ossibl, . . i'm very grateful. but how does he ossiblj , . .,. i'm very grateful. but how does he ossiblj , . .. ., i'm very grateful. but how does he ossiblj , . ., ., possibly square the fact that a leadin: possibly square the fact that a leading clinical _ possibly square the fact that a leading clinical ppe _ possibly square the fact that a leading clinical ppe supplier. possibly square the fact that a | leading clinical ppe supplier to possibly square the fact that a - leading clinical ppe supplier to the nhs, ...

In these patients, we want to avoid as much as possible an over—treatment that can be considered in itself as a new disease. so that's why you want to identify the patients that are not likely to relapse. 0wkin aims to complement everyday clinical practice with its tool. it can already be used in european hospitals, and the company is working on an updated version for those in the uk. what does an oncologist, who's used to having difficult conversations with patients, make of it, though? what we do now in terms of assessment of the risk is to have the standard i information, the standard cli...